Skip to main content
PFE
NYSE Life Sciences

辉瑞CEO批评FDA疫苗领导层，指责忽视员工建议

feedReported by Reuters
Sentiment info
Negative
Importance info
7
Price
$27.4
Mkt Cap
$155.805B
52W Low
$20.915
52W High
$27.94
Market data snapshot near publication time

summarizeSummary

辉瑞CEO Albert Bourla公开批评了美国FDA疫苗部门的领导层，表示当前主任不遵循员工的建议。这位主要制药公司CEO的公开评论表明可能存在与关键监管机构的摩擦或分歧。这种问题可能会影响辉瑞现有疫苗产品线或未来的疫苗候选品的监管途径，可能导致延迟或加剧审查。交易员将关注有关此关系及其对辉瑞疫苗业务的潜在影响的任何进一步发展或澄清。

show_chartPrice Chart

Share this article

Copied!

feed PFE - Latest Insights

PFE
Mar 23, 2026, 12:46 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Pfizer's Lyme Vaccine Shows Strong Efficacy, But Phase 3 Study Misses Key Statistical Mark
Sentiment: Neutral
View Wiseek Article
PFE
Mar 23, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Pfizer's Lyme Vaccine Achieves Over 70% Efficacy in Phase 3, Regulatory Filings Planned
Sentiment: Positive
View Wiseek Article
PFE
Mar 12, 2026, 9:05 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Pfizer Seeks Approval for 320M New Shares, Faces Low Say-on-Pay Support
Sentiment: Negative
View Wiseek Article
PFE
Mar 09, 2026, 7:11 AM EDT
Source: Reuters
Importance Score:
7
Pfizer's Trispecific Antibody Shows Positive Phase 2 Results in Atopic Dermatitis, Advancing to Phase 3
Sentiment: Positive
View Wiseek Article
PFE
Mar 02, 2026, 11:09 AM EST
Source: Reuters
Importance Score:
7
Pfizer CEO Criticizes FDA Vaccine Leadership, Citing Staff Recommendation Disregard
Sentiment: Negative
View Wiseek Article